Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Lutnick Says 'we Trust Anthropic' - Axios
• Snowflake (SNOW) call put ratio 1.6 calls to 1 put into quarter results
• Curaleaf pushes back on Aurora's rejection of takeover bid